Episurf Medical AB (publ) (EPIS-B.ST)
SEK 0.13
(-2.03%)
SEK 0.13
(-2.03%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -52.7 Million SEK | 64.63% |
| 2022 | -149 Million SEK | 36.6% |
| 2021 | -235 Million SEK | -55.53% |
| 2020 | -151.1 Million SEK | -678.87% |
| 2019 | -19.4 Million SEK | 23.92% |
| 2018 | -25.5 Million SEK | 64.23% |
| 2017 | -71.27 Million SEK | -73.3% |
| 2016 | -41.13 Million SEK | 60.44% |
| 2015 | -103.96 Million SEK | -201.42% |
| 2014 | -34.48 Million SEK | 49.92% |
| 2013 | -68.86 Million SEK | -198.46% |
| 2012 | -23.07 Million SEK | 41.75% |
| 2011 | -39.61 Million SEK | -464.62% |
| 2010 | -7.01 Million SEK | -2275.93% |
| 2009 | -295.29 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -82.8 Million SEK | -176.92% |
| 2024 Q3 | -63.9 Million SEK | 23.07% |
| 2024 Q1 | -29.9 Million SEK | 43.26% |
| 2023 Q4 | -52.7 Million SEK | 28.88% |
| 2023 Q3 | -74.1 Million SEK | 25.23% |
| 2023 Q2 | -99.1 Million SEK | 18.97% |
| 2023 FY | -52.7 Million SEK | 64.63% |
| 2023 Q1 | -122.3 Million SEK | 17.92% |
| 2022 FY | -149 Million SEK | 36.6% |
| 2022 Q4 | -149 Million SEK | 13.62% |
| 2022 Q3 | -172.5 Million SEK | 9.59% |
| 2022 Q2 | -190.8 Million SEK | 9.4% |
| 2022 Q1 | -210.6 Million SEK | 10.38% |
| 2021 Q1 | -134.1 Million SEK | 11.25% |
| 2021 FY | -235 Million SEK | -55.53% |
| 2021 Q3 | -101 Million SEK | 14.33% |
| 2021 Q4 | -235 Million SEK | -132.67% |
| 2021 Q2 | -117.9 Million SEK | 12.08% |
| 2020 Q3 | -102.1 Million SEK | 12.21% |
| 2020 Q4 | -151.1 Million SEK | -47.99% |
| 2020 FY | -151.1 Million SEK | -678.87% |
| 2020 Q2 | -116.3 Million SEK | -44.65% |
| 2020 Q1 | -80.4 Million SEK | -314.43% |
| 2019 Q1 | -3.8 Million SEK | 85.1% |
| 2019 Q2 | -52.1 Million SEK | -1271.05% |
| 2019 Q3 | -36.2 Million SEK | 30.52% |
| 2019 Q4 | -19.4 Million SEK | 46.41% |
| 2019 FY | -19.4 Million SEK | 23.92% |
| 2018 Q2 | -44.9 Million SEK | 20.95% |
| 2018 FY | -25.5 Million SEK | 64.23% |
| 2018 Q4 | -25.5 Million SEK | 0.39% |
| 2018 Q3 | -25.6 Million SEK | 42.98% |
| 2018 Q1 | -56.8 Million SEK | 20.31% |
| 2017 Q3 | -87.54 Million SEK | 15.12% |
| 2017 FY | -71.27 Million SEK | -73.3% |
| 2017 Q4 | -71.27 Million SEK | 18.58% |
| 2017 Q2 | -103.13 Million SEK | 18.99% |
| 2017 Q1 | -127.32 Million SEK | -209.55% |
| 2016 Q3 | -56.13 Million SEK | 21.59% |
| 2016 Q4 | -41.13 Million SEK | 26.73% |
| 2016 FY | -41.13 Million SEK | 60.44% |
| 2016 Q1 | -88.79 Million SEK | 13.72% |
| 2016 Q2 | -71.58 Million SEK | 19.38% |
| 2015 Q4 | -102.9 Million SEK | 12.64% |
| 2015 Q1 | -25.58 Million SEK | 25.82% |
| 2015 FY | -103.96 Million SEK | -201.42% |
| 2015 Q3 | -117.79 Million SEK | -711.66% |
| 2015 Q2 | -14.51 Million SEK | 43.28% |
| 2014 Q1 | -59.44 Million SEK | 13.68% |
| 2014 FY | -34.48 Million SEK | 49.92% |
| 2014 Q4 | -34.48 Million SEK | 16.69% |
| 2014 Q3 | -41.39 Million SEK | 19.29% |
| 2014 Q2 | -51.28 Million SEK | 13.72% |
| 2013 Q2 | -67.55 Million SEK | -278.03% |
| 2013 Q1 | -17.86 Million SEK | 22.56% |
| 2013 Q3 | -75.61 Million SEK | -11.94% |
| 2013 Q4 | -68.86 Million SEK | 8.93% |
| 2013 FY | -68.86 Million SEK | -198.46% |
| 2012 Q2 | -32.02 Million SEK | 11.4% |
| 2012 Q1 | -36.14 Million SEK | 8.76% |
| 2012 FY | -23.07 Million SEK | 41.75% |
| 2012 Q4 | -23.07 Million SEK | 20.05% |
| 2012 Q3 | -28.86 Million SEK | 9.87% |
| 2011 Q3 | -43.65 Million SEK | 10.33% |
| 2011 Q2 | -48.68 Million SEK | -840.33% |
| 2011 Q1 | -5.17 Million SEK | 26.21% |
| 2011 FY | -39.61 Million SEK | -464.62% |
| 2011 Q4 | -39.61 Million SEK | 9.25% |
| 2010 FY | -7.01 Million SEK | -2275.93% |
| 2010 Q4 | -7.01 Million SEK | 0.0% |
| 2009 FY | -295.29 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | -49.933% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 104.295% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 104.295% |
| Arcoma AB | -1.12 Million SEK | -4571.986% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | 147.961% |
| BICO Group AB (publ) | 927.9 Million SEK | 105.679% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | 140.916% |
| CellaVision AB (publ) | -56.94 Million SEK | 7.45% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | -254.238% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | -523.284% |
| C-Rad AB (publ) | -127.6 Million SEK | 58.699% |
| Duearity AB (publ) | 10.23 Million SEK | 615.101% |
| Dignitana AB (publ) | 13.07 Million SEK | 502.998% |
| Getinge AB (publ) | 5.4 Billion SEK | 100.974% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | -50.343% |
| Iconovo AB (publ) | -10.75 Million SEK | -389.989% |
| Integrum AB (publ) | -10.47 Million SEK | -403.029% |
| Luxbright AB (publ) | -13.83 Million SEK | -280.96% |
| Mentice AB (publ) | -49.56 Million SEK | -6.327% |
| OssDsign AB (publ) | -162.78 Million SEK | 67.627% |
| Paxman AB (publ) | -11.41 Million SEK | -361.835% |
| Promimic AB (publ) | -50.32 Million SEK | -4.723% |
| Qlife Holding AB (publ) | 19.07 Million SEK | 376.35% |
| SciBase Holding AB (publ) | -27.32 Million SEK | -92.871% |
| ScandiDos AB (publ) | -1.53 Million SEK | -3342.195% |
| Sectra AB (publ) | -772.85 Million SEK | 93.181% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 76.771% |
| Senzime AB (publ) | -139.54 Million SEK | 62.233% |
| SpectraCure AB (publ) | -50.23 Million SEK | -4.909% |
| Stille AB | -178.5 Million SEK | 70.477% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 104.292% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 75.449% |